Evidence map›Paper›PMID 26408255›Full record

ArticleNeoplasia (New York, N.Y.)2015

Modeling selective elimination of quiescent cancer cells from bone marrow.

Stephen P Cavnar, Andrew D Rickelmann, Kaille F Meguiar, Annie Xiao, Joseph Dosch, Brendan M Leung, Sasha Cai Lesher-Perez, Shashank Chitta, Kathryn E Luker, Shuichi Takayama and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Frontiers in cell and developmental biology · 2020
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Stephen P CavnarDepartment of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI 48109; Biointerfaces Institute, University of Michigan College of Engineering, Ann Arbor, MI 48109.
Andrew D RickelmannDepartment of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109; Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109.
Kaille F MeguiarDepartment of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109; Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109.
Annie XiaoDepartment of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109; Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109.
Joseph DoschDepartment of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109.
Brendan M LeungDepartment of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI 48109; Biointerfaces Institute, University of Michigan College of Engineering, Ann Arbor, MI 48109.
Sasha Cai Lesher-PerezDepartment of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI 48109; Biointerfaces Institute, University of Michigan College of Engineering, Ann Arbor, MI 48109.
Shashank ChittaDepartment of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109; Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109.
Kathryn E LukerDepartment of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109; Department of Macromolecular Science and Engineering, University of Michigan College of Engineering, Ann Arbor, MI 48109.
Shuichi TakayamaDepartment of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI 48109; Biointerfaces Institute, University of Michigan College of Engineering, Ann Arbor, MI 48109; Department of Macromolecular Science and Engineering, University of Michigan College of Engineering, Ann Arbor, MI 48109.
Gary D LukerDepartment of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI 48109; Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109; Center for Molecular Imaging, Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109. Electronic address: gluker@med.umich.edu.
University of Michigan–Ann Arbor · USBioSurfaces (United States) · US

Funding

Proteogenomics of Cancer Training ProgramT32CA140044 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAO, ARVIND, SARTOR, MAUREEN AGNES · 2010 to 2024
$3.9M
Modeling Therapy of Disseminated Cancer Cells in Bone Marrow (PQ 17)R01CA170198 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKER, GARY D, TAKAYAMA, SHUICHI · 2012 to 2015
$1.4M
Olympus FV1000-MPE Confocal & Multi-Photon Imaging SystemS10RR028819 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKER, GARY D · 2010 to 2010
$940k
NCI NIH HHS R01 CA170198NCI NIH HHS R01CA170198NCI NIH HHS T32 CA140044NCRR NIH HHS 1S10RR028819NCRR NIH HHS S10 RR028819
6 · The paper itself

Abstract

Patients with many types of malignancy commonly harbor quiescent disseminated tumor cells in bone marrow. These cells frequently resist chemotherapy and may persist for years before proliferating as recurrent metastases. To test for compounds that eliminate quiescent cancer cells, we established a new 384-well 3D spheroid model in which small numbers of cancer cells reversibly arrest in G1/G0 phase of the cell cycle when cultured with bone marrow stromal cells. Using dual-color bioluminescence imaging to selectively quantify viability of cancer and stromal cells in the same spheroid, we identified single compounds and combination treatments that preferentially eliminated quiescent breast cancer cells but not stromal cells. A treatment combination effective against malignant cells in spheroids also eliminated breast cancer cells from bone marrow in a mouse xenograft model. This research establishes a novel screening platform for therapies that selectively target quiescent tumor cells, facilitating identification of new drugs to prevent recurrent cancer.

Indexed as

AnimalsAntineoplastic AgentsBone Marrow CellsBreast NeoplasmsCell Culture TechniquesCell Cycle CheckpointsCell Line, TumorCell SurvivalCoculture TechniquesDrug Screening Assays, AntitumorDrug SynergismFemaleHumansLuminescent MeasurementsMiceMicroscopy, FluorescenceAntineoplastic Agents

Identifiers

PMID26408255
PMCPMC4674483
OpenAlexW1922125428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.